glp-1 small molecule agonist agonists A Small-Molecule Oral Agonist of

all studies were designed to assess noninferiority to placebo in terms of CV safety and superiority to placebo in terms of efficacy (except for REWIND, designed to evaluate superiority to placebo in terms of CV safety)

N., Xavier E

[DOI] [PMC free article] [PubMed] [Google Scholar] 128.Joshi GP, Abdelmalak BB, Weigel WA, et al

[DOI] [PMC free article] [PubMed] [Google Scholar] 82.Simonsen E., Lund L.C., Ernst M.T., et al

We suggest that a pathophysiological window of abnormal circulating androgen levels, with serum testosterone concentrations at a level shared by men with androgen deficiency and women with androgen excess, could increase the risk of IIH